BRAF and thyroid cancer: Among the 293 mutation-positive specimens, 287 cases (97.9%) were identified as thyroid cancer, including 15 NIFTP, whereas six mutation-positive specimens were confirmed as follicular adenoma (four with RAS-positive and two with BRAF-positive).